Expertise in
8
conditions

Marjolein M. Van Der Poel-Van Der Wal

Maastricht, LI, NL 
Expertise in
8
conditions
Maastricht, LI, NL 

Overview

Marjolein Van Der Poel-Van Der Wal practices practicing medicine in Maastricht, Netherlands.

Van Der Poel-Van Der Wal is highly rated in 8 conditions, according to our data. Their clinical expertise encompasses B-Cell Lymphoma, Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Chronic Graft Versus Host Disease (cGvHD), and Bone Marrow Transplant.

They are actively involved in clinical research, co-authoring 70 peer reviewed articles and participating in 4 clinical trials.

Locations

Maastricht, LI, Netherlands
Other Locations
Utrecht, UT, Netherlands

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase II Study Evaluating the Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk Diffuse Large B-cell Lymphoma
A Phase II Study Evaluating the Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk Diffuse Large B-cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: January 05, 2026
Intervention Type: Drug
Study Drug: Atezolizumab
Study Phase: Phase 2
A Phase II Study Evaluating the Effect of DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Patients With Newly Diagnosed High Grade B Cell Lymphoma (HGBL) With MYC and BCL2 and/or BCL6 Rearrangements
A Phase II Study Evaluating the Effect of DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Patients With Newly Diagnosed High Grade B Cell Lymphoma (HGBL) With MYC and BCL2 and/or BCL6 Rearrangements
Enrollment Status: Active_not_recruiting
Publish Date: February 14, 2024
Intervention Type: Drug
Study Drug: Pembrolizumab
Study Phase: Phase 2
10-day Decitabine Versus Conventional Chemotherapy (3+7) Followed by Allografting in AML Patients ≥ 60 Years: a Randomized Phase III Study of the EORTC Leukemia Group, CELG, GIMEMA and German MDS Study Group
10-day Decitabine Versus Conventional Chemotherapy (3+7) Followed by Allografting in AML Patients ≥ 60 Years: a Randomized Phase III Study of the EORTC Leukemia Group, CELG, GIMEMA and German MDS Study Group
Enrollment Status: Unknown
Publish Date: February 15, 2023
Intervention Type: Drug
Study Drugs: Decitabine, Daunorubicin, Cytarabine, Idarubicin, Etoposide
Study Phase: Phase 3
A Survivorship Project to UnerstAnd and to impRove Long-Term Outcomes for Acute Myeloid Leukemia Patients (SPARTA): the Sparta Platform
A Survivorship Project to UnerstAnd and to impRove Long-Term Outcomes for Acute Myeloid Leukemia Patients (SPARTA): the Sparta Platform
Enrollment Status: Unknown
Publish Date: March 04, 2020
Intervention Type: Other
View 3 Less Clinical Trials

70 Total Publications

Risk of thrombosis and bleeding following CAR T-cell therapy: Insights from the Dutch "Follow that CAR!" registry.
Risk of thrombosis and bleeding following CAR T-cell therapy: Insights from the Dutch "Follow that CAR!" registry.
Journal: HemaSphere
Published: March 19, 2026

Frequently Asked Questions about Marjolein M. Van Der Poel-Van Der Wal

Is Marjolein M. Van Der Poel-Van Der Wal a top-rated expert for B-Cell Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Marjolein M. Van Der Poel-Van Der Wal is classified as an Distinguished expert for B-Cell Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Marjolein M. Van Der Poel-Van Der Wal participate in research or clinical trials?

Yes. Marjolein M. Van Der Poel-Van Der Wal has published 70 articles and abstracts on conditions like B-Cell Lymphoma. You can view a list of Marjolein M. Van Der Poel-Van Der Wal's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Van Der Poel-Van Der Wal's expertise for a condition
ConditionClose
    View All 20 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile